Patents by Inventor Guobin Miao

Guobin Miao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MK2 inhibitors and uses thereof
    Patent number: 12668598
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the MK2 inhibitors of the Formula:
    Type: Grant
    Filed: October 26, 2023
    Date of Patent: June 30, 2026
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xirui Hu, Lixin Qiao, Boris Seletsky, Matthew Patton, Min Cao, Farid van der Mei, Guobin Miao, Ivar McDonald, Carolyn Dzierba
  • COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE
    Publication number: 20260109708
    Abstract: The present disclosure provides compounds and compositions useful for degrading MK2 kinase.
    Type: Application
    Filed: February 6, 2024
    Publication date: April 23, 2026
    Inventors: Farid VAN DER MEI, Guobin MIAO, Lixin QIAO
  • Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3
    Publication number: 20260028343
    Abstract: Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 29, 2026
    Applicant: Celgene Corporation
    Inventors: Farid van der Mei, Guobin Miao, Rulin Ma, Laura Akullian D'Agostino, Kurt Armbrust
  • HETEROCYCLIC PAD4 INHIBITORS
    Publication number: 20250353848
    Abstract: The disclosure generally relates to 3,5,6,7-tetrahydro-8H-imidazo[4,5-b][1,6]naphthyridin-8-one compounds of Formula I, which are inhibitors of PAD4, methods for preparing these compounds, pharmaceutical compositions comprising these compounds and uses of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 20, 2025
    Inventors: Alyssa H. Antropow, Boris M. Seletsky, Audrey Graham Ross, Xiao Zhu, Paul E. Gormisky, Guobin Miao
  • Heterocyclic PAD4 inhibitors
    Patent number: 12473304
    Abstract: wherein and X1-X6 and R1-R8, along with other variables are as defined herein. The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: November 18, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kumaravel Selvakumar, Venkatram Reddy Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Hernan Cuervo
  • HETEROCYCLIC PAD4 INHIBITORS
    Publication number: 20250346592
    Abstract: The disclosure generally relates to compounds of Formula I, comprising a 1,6,7,8-tetrahydro-5H-imidazo[4,5-g][1,6]isoquinolin-5-one moiety directly bonded to an azaindole or indole moiety, such compounds as inhibitors of PAD4, methods for preparing these compounds pharmaceutical compositions comprising these compounds and uses of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 13, 2025
    Inventors: Alyssa H. Antropow, Boris M. Seletsky, Audrey Graham Ross, Xiao Zhu, Paul E. Gormisky, Guobin Miao, Deqiang Niu, Zhendong Zhu, Julio Hernan Cuervo
  • TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS
    Publication number: 20240391931
    Abstract: Provided herein are tricyclic fused pyrimidine compounds, and pharmaceutically acceptable salts thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Application
    Filed: August 4, 2022
    Publication date: November 28, 2024
    Inventors: Laura Akullian D'Agostino, Xinchao Chen, Claudio Emundo Chuaqui, Hormoz Mazdiyasni, Guobin Miao, Deqiang Niu
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20240190890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the MK2 inhibitors of the Formula:
    Type: Application
    Filed: October 26, 2023
    Publication date: June 13, 2024
    Inventors: Xirui Hu, Lixin Qiao, Boris Seletsky, Matthew Patton, Min Cao, Farid van der Mei, Guobin Miao, Ivar McDonald, Carolyn Dzierba
  • HETEROCYCLIC PAD4 INHIBITORS
    Publication number: 20230167131
    Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 1, 2023
    Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo